drugset
Drugs / Rexlemestrocel-L
last change Jul 2024 re-read 3 minutes ago

Rexlemestrocel-L

also known as NeoFuse · MPC · Revascor

Cell therapy

Developed for
intervertebral disk degenerative disorder · spinal stenosis · spondylolisthesis · cervical disk degenerative disorder · type 2 diabetes mellitus · atrioventricular septal defect · diabetic kidney disease · heart failure
+1 more · hypoplastic left heart syndrome
Investigated by
Mesoblast, Inc. · Boston Children's Hospital · Quintiles, Inc.

Trials 11

today NCT06325566 · Ph 3 NCT03079401 · Ph 1/2 NCT02412735 · Ph 3 NCT02032004 · Ph 3 NCT01843387 · Ph 1/2 NCT01576328 · Ph 1/2 NCT01097486 · Ph 2 NCT01106417 · Ph 1/2 NCT00996073 · Ph 2 NCT00810212 · Ph 1/2 NCT00549913 · Ph 1/2
200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/26 trials
Phase 1/2 NCT03079401 Nov 2017 → Dec 2022 atrioventricular septal defect, hypoplastic left heart syndrome Boston Children's Hospital Unknown No outcome recorded
Phase 1/2 NCT01843387 Jul 2013 → Sep 2014 diabetic kidney disease, type 2 diabetes mellitus Mesoblast, Inc. Completed No outcome recorded
Phase 1/2 NCT01576328 Apr 2012 → Oct 2013 type 2 diabetes mellitus Mesoblast, Inc. Completed No outcome recorded
Phase 1/2 NCT01106417 Jun 2010 → May 2012 cervical disk degenerative disorder, spinal stenosis, spondylolisthesis Mesoblast, Inc. Completed No outcome recorded
Phase 1/2 NCT00810212 Nov 2008 → Nov 2011 intervertebral disk degenerative disorder, spinal stenosis, spondylolisthesis Mesoblast, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT00549913 Oct 2007 → Aug 2013 intervertebral disk degenerative disorder, spinal stenosis, spondylolisthesis Mesoblast, Inc. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01097486 Jun 2010 → Jul 2013 cervical disk degenerative disorder, spinal stenosis, spondylolisthesis Mesoblast, Inc. Completed No outcome recorded
Phase 2 NCT00996073 Sep 2009 → Jul 2012 intervertebral disk degenerative disorder, spinal stenosis, spondylolisthesis Mesoblast, Inc. Completed No outcome recorded
Phase 33 trials
Phase 3 NCT06325566 Jul 2024 → Jul 2027 expected intervertebral disk degenerative disorder Mesoblast, Inc. Active not recruiting No outcome recorded
Phase 3 NCT02412735 Mar 2015 → May 2020 intervertebral disk degenerative disorder Mesoblast, Inc. Completed No outcome recorded
Phase 3 NCT02032004 Mar 2014 → Jan 2020 heart failure Mesoblast, Inc. Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Rexlemestrocel-L “The study was a dose-escalating randomized placebo-controlled trial assessing one intravenous (IV) infusion of MPCs (rexlemestrocel-L; Mesoblast Inc.) 0.3 × 10(6)/kg (n = 15),...” PMID 26153271 ↗ Jul 2015
5

“single intravenous (IV) infusion of allogeneic MPC (United States adopted name: rexlemestrocel-L) 150×106 (n=10), 300×106 (n=10) or placebo (n=10)” PMID 27743903 ↗ Sep 2016

NCT02032004 ↗

NCT06325566 ↗

NCT03079401 ↗

NCT02412735 ↗
Known as MPC “single intravenous (IV) infusion of allogeneic MPC (United States adopted name: rexlemestrocel-L) 150×106 (n=10), 300×106 (n=10) or placebo (n=10)” PMID 27743903 ↗ Sep 2016
Known as NeoFuse ClinicalTrials.gov intervention name — accepted as the source's own label NCT01106417 ↗
4

NCT00549913 ↗

NCT00996073 ↗

NCT01097486 ↗

NCT00810212 ↗
Known as Revascor ChEMBL registry synonym — accepted as the source's own label CHEMBL3545318 ↗
Modality Cell therapy “immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse)” NCT00549913 ↗
Route Intravenous “one intravenous (IV) infusion of MPCs (rexlemestrocel-L; Mesoblast Inc.)” PMID 26153271 ↗ Jul 2015